BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Damaskos C, Garmpis N, Valsami S, Kontos M, Spartalis E, Kalampokas T, Kalampokas E, Athanasiou A, Moris D, Daskalopoulou A. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. Anticancer Res. 2017;37:35-46. [PMID: 28011471 DOI: 10.21873/anticanres.11286] [Cited by in Crossref: 103] [Cited by in F6Publishing: 94] [Article Influence: 20.6] [Reference Citation Analysis]
Number Citing Articles
1 Prakash A, Garcia-Moreno JF, Brown JAL, Bourke E. Clinically Applicable Inhibitors Impacting Genome Stability. Molecules 2018;23:E1166. [PMID: 29757235 DOI: 10.3390/molecules23051166] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
2 Armstrong H, Bording-Jorgensen M, Wine E. The Multifaceted Roles of Diet, Microbes, and Metabolites in Cancer. Cancers (Basel) 2021;13:767. [PMID: 33673140 DOI: 10.3390/cancers13040767] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sher G, Salman NA, Khan AQ, Prabhu KS, Raza A, Kulinski M, Dermime S, Haris M, Junejo K, Uddin S. Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications. Semin Cancer Biol 2020:S1044-579X(20)30181-4. [PMID: 32858230 DOI: 10.1016/j.semcancer.2020.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Wang J, Zhang Q, Li Q, Mu Y, Jing J, Li H, Li W, Wang J, Yu G, Wang X, Ouyang Q, Hao J, Lu L, Zhou L, Guan J, Li Q, Xu B. Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. Target Oncol 2021. [PMID: 34196874 DOI: 10.1007/s11523-021-00823-4] [Reference Citation Analysis]
5 Chen CY, Chen CC, Chuang WY, Leu YL, Ueng SH, Hsueh C, Yeh CT, Wang TH. Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells. Front Oncol 2020;10:216. [PMID: 32158695 DOI: 10.3389/fonc.2020.00216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lipska K, Gumieniczek A, Filip AA. Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges. Acta Pharm 2020;70:291-301. [PMID: 32074065 DOI: 10.2478/acph-2020-0021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
7 Conte M, De Palma R, Altucci L. HDAC inhibitors as epigenetic regulators for cancer immunotherapy. Int J Biochem Cell Biol 2018;98:65-74. [PMID: 29535070 DOI: 10.1016/j.biocel.2018.03.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
8 Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, Zannella C, Franci G. Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers (Basel) 2021;13:2761. [PMID: 34199429 DOI: 10.3390/cancers13112761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Farhan M, Ullah MF, Faisal M, Farooqi AA, Sabitaliyevich UY, Biersack B, Ahmad A. Differential Methylation and Acetylation as the Epigenetic Basis of Resveratrol's Anticancer Activity. Medicines (Basel) 2019;6:E24. [PMID: 30781847 DOI: 10.3390/medicines6010024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
10 Puustinen MC, Sistonen L. Molecular Mechanisms of Heat Shock Factors in Cancer. Cells 2020;9:E1202. [PMID: 32408596 DOI: 10.3390/cells9051202] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
11 AboulWafa OM, Daabees HMG, Hammad A, Badawi WA. New functionalized 6-thienylpyrimidine-5-carbonitriles as antiproliferative agents against human breast cancer cells. Arch Pharm (Weinheim) 2021;:e2100177. [PMID: 34347303 DOI: 10.1002/ardp.202100177] [Reference Citation Analysis]
12 Varghese B, Del Gaudio N, Cobellis G, Altucci L, Nebbioso A. KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches. Front Oncol 2021;11:750315. [PMID: 34778065 DOI: 10.3389/fonc.2021.750315] [Reference Citation Analysis]
13 Mondal P, Natesh J, Penta D, Meeran SM. Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update. Semin Cancer Biol 2020:S1044-579X(20)30266-2. [PMID: 33309850 DOI: 10.1016/j.semcancer.2020.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Martelli A, Citi V, Testai L, Brogi S, Calderone V. Organic Isothiocyanates as Hydrogen Sulfide Donors. Antioxid Redox Signal 2020;32:110-44. [PMID: 31588780 DOI: 10.1089/ars.2019.7888] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
15 Romeo MA, Gilardini Montani MS, Benedetti R, Garufi A, D'Orazi G, Cirone M. PBA Preferentially Impairs Cell Survival of Glioblastomas Carrying mutp53 by Reducing Its Expression Level, Stabilizing wtp53, Downregulating the Mevalonate Kinase and Dysregulating UPR. Biomolecules 2020;10:E586. [PMID: 32290231 DOI: 10.3390/biom10040586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Bridgeman S, Ellison G, Newsholme P, Mamotte C. The HDAC Inhibitor Butyrate Impairs β Cell Function and Activates the Disallowed Gene Hexokinase I. Int J Mol Sci 2021;22:13330. [PMID: 34948127 DOI: 10.3390/ijms222413330] [Reference Citation Analysis]
17 Nandy D, Rajam SM, Dutta D. A three layered histone epigenetics in breast cancer metastasis. Cell Biosci 2020;10:52. [PMID: 32257110 DOI: 10.1186/s13578-020-00415-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Householder KT, DiPerna DM, Chung EP, Luning AR, Nguyen DT, Stabenfeldt SE, Mehta S, Sirianni RW. pH driven precipitation of quisinostat onto PLA-PEG nanoparticles enables treatment of intracranial glioblastoma. Colloids Surf B Biointerfaces 2018;166:37-44. [PMID: 29533842 DOI: 10.1016/j.colsurfb.2018.02.048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
19 Humphries B, Wang Z, Yang C. MicroRNA Regulation of Epigenetic Modifiers in Breast Cancer. Cancers (Basel) 2019;11:E897. [PMID: 31252590 DOI: 10.3390/cancers11070897] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
20 Sultana F, Manasa KL, Shaik SP, Bonam SR, Kamal A. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Curr Med Chem 2019;26:7212-80. [PMID: 29852860 DOI: 10.2174/0929867325666180530094120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
21 Dawood M, Elbadawi M, Böckers M, Bringmann G, Efferth T. Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells. Biomed Pharmacother 2020;129:110454. [PMID: 32768947 DOI: 10.1016/j.biopha.2020.110454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
22 Abdel-Hafiz HA. Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. Diseases 2017;5:E16. [PMID: 28933369 DOI: 10.3390/diseases5030016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
23 Hernández-Lemus E, Reyes-Gopar H, Espinal-Enríquez J, Ochoa S. The Many Faces of Gene Regulation in Cancer: A Computational Oncogenomics Outlook. Genes (Basel) 2019;10:E865. [PMID: 31671657 DOI: 10.3390/genes10110865] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
24 Injinari N, Amini-Farsani Z, Yadollahi-Farsani M, Teimori H. Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer. Life Sci 2021;269:119027. [PMID: 33453248 DOI: 10.1016/j.lfs.2021.119027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Juengel E, Najafi R, Rutz J, Maxeiner S, Makarevic J, Roos F, Tsaur I, Haferkamp A, Blaheta RA. HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells. Oncotarget 2017;8:110016-28. [PMID: 29299126 DOI: 10.18632/oncotarget.22454] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
26 Bieszczad B, Garbicz D, Świtalska M, Dudek MK, Warszycki D, Wietrzyk J, Grzesiuk E, Mieczkowski A. Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues. Pharmaceuticals (Basel) 2021;14:851. [PMID: 34577551 DOI: 10.3390/ph14090851] [Reference Citation Analysis]
27 Zhang Y, Nalawansha DA, Herath KE, Andrade R, Pflum MKH. Differential profiles of HDAC1 substrates and associated proteins in breast cancer cells revealed by trapping. Mol Omics 2021;17:544-53. [PMID: 33885658 DOI: 10.1039/d0mo00047g] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wu HJ, Chu PY. Epigenetic Regulation of Breast Cancer Stem Cells Contributing to Carcinogenesis and Therapeutic Implications. Int J Mol Sci 2021;22:8113. [PMID: 34360879 DOI: 10.3390/ijms22158113] [Reference Citation Analysis]
29 Ruzzolini J, Laurenzana A, Andreucci E, Peppicelli S, Bianchini F, Carta F, Supuran CT, Romanelli MN, Nediani C, Calorini L. A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer. J Enzyme Inhib Med Chem 2020;35:391-7. [PMID: 31865754 DOI: 10.1080/14756366.2019.1706090] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
30 Shan NL, Shin Y, Yang G, Furmanski P, Suh N. Breast cancer stem cells: A review of their characteristics and the agents that affect them. Mol Carcinog 2021;60:73-100. [PMID: 33428807 DOI: 10.1002/mc.23277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Muhammad A, Katsayal BS, Forcados GE, Malami I, Abubakar IB, Kandi AI, Idris AM, Yusuf S, Musa SM, Monday N, Umar ZS. In silico predictions on the possible mechanism of action of selected bioactive compounds against breast cancer. In Silico Pharmacol 2020;8:4. [PMID: 33194532 DOI: 10.1007/s40203-020-00057-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Chen MC, Lin YC, Liao YH, Liou JP, Chen CH. MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells. Cancers (Basel) 2019;11:E1617. [PMID: 31652644 DOI: 10.3390/cancers11101617] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
33 Zhang Q, Dai Y, Cai Z, Mou L. HDAC Inhibitors: Novel Immunosuppressants for Allo- and Xeno- Transplantation. ChemistrySelect 2018;3:176-87. [DOI: 10.1002/slct.201702295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
34 Chen YC, Liu YC, El-Shazly M, Wu TY, Chang JG, Wu YC. Antrodia cinnamomea, a Treasured Medicinal Mushroom, Induces Growth Arrest in Breast Cancer Cells, T47D Cells: New Mechanisms Emerge. Int J Mol Sci 2019;20:E833. [PMID: 30769922 DOI: 10.3390/ijms20040833] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
35 Gao Y, Zhang H, Lirussi F, Garrido C, Ye XY, Xie T. Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. Biochem Pharmacol 2020;182:114224. [PMID: 32956642 DOI: 10.1016/j.bcp.2020.114224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 El Sayed R, El Jamal L, El Iskandarani S, Kort J, Abdel Salam M, Assi H. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. Front Oncol 2019;9:510. [PMID: 31281796 DOI: 10.3389/fonc.2019.00510] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
37 Hosseinzadeh P, Watson PR, Craven TW, Li X, Rettie S, Pardo-Avila F, Bera AK, Mulligan VK, Lu P, Ford AS, Weitzner BD, Stewart LJ, Moyer AP, Di Piazza M, Whalen JG, Greisen PJ, Christianson DW, Baker D. Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites. Nat Commun 2021;12:3384. [PMID: 34099674 DOI: 10.1038/s41467-021-23609-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Nakagawa H, Yui Y, Sasagawa S, Itoh K. Evidence for intrathecal sodium butyrate as a novel option for leptomeningeal metastasis. J Neurooncol 2018;139:43-50. [PMID: 29626288 DOI: 10.1007/s11060-018-2852-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Dos Santos MB, Bertholin Anselmo D, de Oliveira JG, Jardim-Perassi BV, Alves Monteiro D, Silva G, Gomes E, Lucia Fachin A, Marins M, de Campos Zuccari DAP, Octavio Regasini L. Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells. J Enzyme Inhib Med Chem 2019;34:1093-9. [PMID: 31117836 DOI: 10.1080/14756366.2019.1615485] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
40 Gupta R, Ambasta RK, Kumar P. Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders. Life Sci 2020;243:117278. [PMID: 31926248 DOI: 10.1016/j.lfs.2020.117278] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
41 Riley PA. Epimutation and Cancer: Carcinogenesis Viewed as Error-Prone Inheritance of Epigenetic Information. J Oncol 2018;2018:2645095. [PMID: 29971105 DOI: 10.1155/2018/2645095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Yang H, Shan W, Zhu F, Wu J, Wang Q. Ketone Bodies in Neurological Diseases: Focus on Neuroprotection and Underlying Mechanisms. Front Neurol 2019;10:585. [PMID: 31244753 DOI: 10.3389/fneur.2019.00585] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 17.7] [Reference Citation Analysis]
43 Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Wahba B, Anbalagan M, Rowan B, Abazeed ME, Bunnell BA, Moroz K, Miele L, Rhodes LV, Jones SD, Martin EC, Collins-Burow BM, Burow ME. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model. BMC Cancer 2019;19:205. [PMID: 30845999 DOI: 10.1186/s12885-019-5401-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
44 Schizas D, Mastoraki A, Naar L, Tsilimigras DI, Katsaros I, Fragkiadaki V, Karachaliou GS, Arkadopoulos N, Liakakos T, Moris D. Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role. Curr Med Chem 2020;27:6099-111. [PMID: 31309879 DOI: 10.2174/0929867326666190712160842] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
45 Kyaw MTH, Yamaguchi Y, Choijookhuu N, Yano K, Takagi H, Takahashi N, Synn Oo P, Sato K, Hishikawa Y. The HDAC Inhibitor, SAHA, Combined with Cisplatin Synergistically Induces Apoptosis in Alpha-fetoprotein-producing Hepatoid Adenocarcinoma Cells. Acta Histochem Cytochem 2019;52:1-8. [PMID: 30923410 DOI: 10.1267/ahc.18044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ming J, Wu S, You T, Wang X, Yu C, Luo P, Zhang A, Pan X. Histone Deacetylation in the Promoter of p16 Is Involved in Fluoride-Induced Human Osteoblast Activation via the Inhibition of Sp1 Binding. Biol Trace Elem Res 2019;188:373-83. [PMID: 29931577 DOI: 10.1007/s12011-018-1413-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
47 Buocikova V, Rios-Mondragon I, Pilalis E, Chatziioannou A, Miklikova S, Mego M, Pajuste K, Rucins M, Yamani NE, Longhin EM, Sobolev A, Freixanet M, Puntes V, Plotniece A, Dusinska M, Cimpan MR, Gabelova A, Smolkova B. Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives. Cancers (Basel) 2020;12:E3622. [PMID: 33287297 DOI: 10.3390/cancers12123622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
48 Ma L, Qi L, Li S, Yin Q, Liu J, Wang J, She C, Li P, Liu Q, Wang X, Li W. Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients. Thorac Cancer 2020;11:2493-505. [PMID: 32686908 DOI: 10.1111/1759-7714.13561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Shen LS, Jin XY, Wang XM, Tou LZ, Huang J. Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Chin Med J (Engl) 2020;133:1099-108. [PMID: 32265426 DOI: 10.1097/CM9.0000000000000745] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
50 Liu X, Jiang C, Liu G, Wang P, Shi M, Yang M, Zhong Z, Ding S, Li Y, Liu B, Cao Y. Sodium butyrate protects against oxidative stress in human nucleus pulposus cells via elevating PPARγ-regulated Klotho expression. Int Immunopharmacol 2020;85:106657. [PMID: 32554208 DOI: 10.1016/j.intimp.2020.106657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
51 Wójcikowska B, Botor M, Morończyk J, Wójcik AM, Nodzyński T, Karcz J, Gaj MD. Trichostatin A Triggers an Embryogenic Transition in Arabidopsis Explants via an Auxin-Related Pathway. Front Plant Sci 2018;9:1353. [PMID: 30271420 DOI: 10.3389/fpls.2018.01353] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
52 Oh S, Ko JY, Oh C, Yoo KH. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer. In: Song E, Hu H, editors. Translational Research in Breast Cancer. Singapore: Springer; 2017. pp. 287-313. [DOI: 10.1007/978-981-10-6020-5_14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
53 Sharma M, Molehin D, Castro-Piedras I, Martinez EG, Pruitt K. Acetylation of conserved DVL-1 lysines regulates its nuclear translocation and binding to gene promoters in triple-negative breast cancer. Sci Rep 2019;9:16257. [PMID: 31700102 DOI: 10.1038/s41598-019-52723-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
54 Keth J, Johann T, Frey H. Hydroxamic Acid: An Underrated Moiety? Marrying Bioinorganic Chemistry and Polymer Science. Biomacromolecules 2020;21:2546-56. [PMID: 32525665 DOI: 10.1021/acs.biomac.0c00449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
55 Salusso A, Zlocowski N, Mayol GF, Zamponi N, Rópolo AS. Histone methyltransferase 1 regulates the encystation process in the parasite Giardia lamblia. FEBS J 2017;284:2396-409. [DOI: 10.1111/febs.14131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
56 Semaan J, El-Hakim S, Ibrahim JN, Safi R, Elnar AA, El Boustany C. Comparative effect of sodium butyrate and sodium propionate on proliferation, cell cycle and apoptosis in human breast cancer cells MCF-7. Breast Cancer 2020;27:696-705. [PMID: 32095987 DOI: 10.1007/s12282-020-01063-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
57 Wawruszak A, Halasa M, Okon E, Kukula-Koch W, Stepulak A. Valproic Acid and Breast Cancer: State of the Art in 2021. Cancers (Basel) 2021;13:3409. [PMID: 34298623 DOI: 10.3390/cancers13143409] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Huang Y, Yang W, Zeng H, Hu C, Zhang Y, Ding N, Fan G, Shao L, Kuang B. Droxinostat sensitizes human colon cancer cells to apoptotic cell death via induction of oxidative stress. Cell Mol Biol Lett 2018;23:34. [PMID: 30065760 DOI: 10.1186/s11658-018-0101-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
59 Chen J, Zhang J, Shaik NF, Yi B, Wei X, Yang XF, Naik UP, Summer R, Yan G, Xu X, Sun J. The histone deacetylase inhibitor tubacin mitigates endothelial dysfunction by up-regulating the expression of endothelial nitric oxide synthase. J Biol Chem 2019;294:19565-76. [PMID: 31719145 DOI: 10.1074/jbc.RA119.011317] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
60 Škovierová H, Okajčeková T, Strnádel J, Vidomanová E, Halašová E. Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review). Int J Mol Med 2018;41:1187-200. [PMID: 29286071 DOI: 10.3892/ijmm.2017.3320] [Cited by in Crossref: 21] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
61 Qiu Z, Wang J, Wu Y. The Landscape of Histone Modification in Cancer Metastasis. In: Basbinar Y, Calıbası-kocal G, editors. Cancer Metastasis. IntechOpen; 2018. [DOI: 10.5772/intechopen.78383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Lundstrom K. Epigenetics: new possibilities for drug discovery. Future Med Chem 2017;9:437-41. [PMID: 28362126 DOI: 10.4155/fmc-2017-0015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
63 Ramadan WS, Vazhappilly CG, Saleh EM, Menon V, AlAzawi AM, El-Serafi AT, Mansour W, El-Awady R. Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy. Cancers (Basel) 2018;11:E13. [PMID: 30583472 DOI: 10.3390/cancers11010013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
64 Schizas D, Mastoraki A, Naar L, Spartalis E, Tsilimigras DI, Karachaliou GS, Bagias G, Moris D. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World J Gastroenterol 2018; 24(41): 4635-4642 [PMID: 30416311 DOI: 10.3748/wjg.v24.i41.4635] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
65 Wolff B, Jänsch N, Sugiarto WO, Frühschulz S, Lang M, Altintas R, Oehme I, Meyer-almes F. Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors. European Journal of Medicinal Chemistry 2019;184:111756. [DOI: 10.1016/j.ejmech.2019.111756] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
66 Ediriweera MK, Tennekoon KH, Samarakoon SR. Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents. Drug Discovery Today 2019;24:685-702. [DOI: 10.1016/j.drudis.2019.02.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
67 Wang Y, Chen H, Chen Q, Jiao FZ, Zhang WB, Gong ZJ. The Protective Mechanism of CAY10683 on Intestinal Mucosal Barrier in Acute Liver Failure through LPS/TLR4/MyD88 Pathway. Mediators Inflamm 2018;2018:7859601. [PMID: 29725271 DOI: 10.1155/2018/7859601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
68 Marcotte JH, Rattigan DA, Irons RF, Cahill KW, Zhang P, Chang S, Koko KR, Gaughan JP, Carpenter JP, Brown SA, Budak-alpdogan T. The Effect of the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Paclitaxel Treatment on Full-Thickness Wound Healing in Mice. Annals of Plastic Surgery 2018;81:482-6. [DOI: 10.1097/sap.0000000000001519] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
69 Good KV, Martínez de Paz A, Tyagi M, Cheema MS, Thambirajah AA, Gretzinger TL, Stefanelli G, Chow RL, Krupke O, Hendzel M, Missiaen K, Underhill A, Landsberger N, Ausió J. Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity. Epigenetics 2017;12:934-44. [PMID: 29099289 DOI: 10.1080/15592294.2017.1380760] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
70 Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Bunnell BA, Martin EC, Burow ME, Collins-Burow BM. Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. Oncoscience 2018;5:99-108. [PMID: 29854878 DOI: 10.18632/oncoscience.412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
71 Xavier PLP, Müller S, Fukumasu H. Epigenetic Mechanisms in Canine Cancer. Front Oncol 2020;10:591843. [PMID: 33194754 DOI: 10.3389/fonc.2020.591843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
72 Iranpak F, Saberzadeh J, Vessal M, Takhshid MA. Sodium valproate ameliorates aluminum-induced oxidative stress and apoptosis of PC12 cells. Iran J Basic Med Sci 2019;22:1353-8. [PMID: 32128102 DOI: 10.22038/ijbms.2019.36930.8804] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
73 Pająk B, Siwiak-Niedbalska E, Jaśkiewicz A, Sołtyka M, Zieliński R, Domoradzki T, Fokt I, Skóra S, Priebe W. Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model. Biomedicines 2021;9:1749. [PMID: 34944565 DOI: 10.3390/biomedicines9121749] [Reference Citation Analysis]
74 Sukocheva OA, Lukina E, Friedemann M, Menschikowski M, Hagelgans A, Aliev G. The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives. Semin Cancer Biol 2020:S1044-579X(20)30263-7. [PMID: 33301860 DOI: 10.1016/j.semcancer.2020.12.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
75 Szumilak M, Wiktorowska-Owczarek A, Stanczak A. Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance? Molecules 2021;26:2601. [PMID: 33946916 DOI: 10.3390/molecules26092601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Svetličič M, Bomhard A, Sterr C, Brückner F, Płódowska M, Lisowska H, Lundholm L. Alpha Radiation as a Way to Target Heterochromatic and Gamma Radiation-Exposed Breast Cancer Cells. Cells 2020;9:E1165. [PMID: 32397212 DOI: 10.3390/cells9051165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Damaskos C, Garmpis N, Garmpi A, Nikolettos K, Sarantis P, Georgakopoulou VE, Nonni A, Schizas D, Antoniou EA, Karamouzis MV, Nikolettos N, Kontzoglou K, Patsouras A, Voutyritsa E, Syllaios A, Koustas E, Trakas N, Dimitroulis D. Investigational Drug Treatments for Triple-Negative Breast Cancer. J Pers Med 2021;11:652. [PMID: 34357119 DOI: 10.3390/jpm11070652] [Reference Citation Analysis]
78 Mirzaei H, Ghorbani S, Khanizadeh S, Namdari H, Faghihloo E, Akbari A. Histone deacetylases in virus-associated cancers. Rev Med Virol 2020;30:e2085. [PMID: 31743548 DOI: 10.1002/rmv.2085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
79 Davalos V, Martinez-cardus A, Esteller M. The Epigenomic Revolution in Breast Cancer. The American Journal of Pathology 2017;187:2163-74. [DOI: 10.1016/j.ajpath.2017.07.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
80 Meisel JL, Venur VA, Gnant M, Carey L. Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. Am Soc Clin Oncol Educ Book 2018;38:78-86. [PMID: 30231395 DOI: 10.1200/EDBK_201037] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
81 Goldner M, Pandolfi N, Maciel D, Lima J, Sanches S, Pondé N. Combined endocrine and targeted therapy in luminal breast cancer. Expert Rev Anticancer Ther 2021;:1-15. [PMID: 34338570 DOI: 10.1080/14737140.2021.1960160] [Reference Citation Analysis]
82 Shin S, Kim M, Lee SJ, Park KS, Lee CH. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes. Cancer Genomics Proteomics 2017;14:349-62. [PMID: 28871002 DOI: 10.21873/cgp.20045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
83 Rahmani G, Sameri S, Abbasi N, Abdi M, Najafi R. The clinical significance of histone deacetylase-8 in human breast cancer. Pathol Res Pract 2021;220:153396. [PMID: 33691240 DOI: 10.1016/j.prp.2021.153396] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 You W, Steegborn C. Structural Basis of Sirtuin 6 Inhibition by the Hydroxamate Trichostatin A: Implications for Protein Deacylase Drug Development. J Med Chem 2018;61:10922-8. [PMID: 30395713 DOI: 10.1021/acs.jmedchem.8b01455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
85 Gomes MN, Muratov EN, Pereira M, Peixoto JC, Rosseto LP, Cravo PVL, Andrade CH, Neves BJ. Chalcone Derivatives: Promising Starting Points for Drug Design. Molecules 2017;22:E1210. [PMID: 28757583 DOI: 10.3390/molecules22081210] [Cited by in Crossref: 125] [Cited by in F6Publishing: 80] [Article Influence: 25.0] [Reference Citation Analysis]
86 Romoli M, Mazzocchetti P, D'Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, Calabresi P, Costa C. Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. Curr Neuropharmacol. 2019;17:926-946. [PMID: 30592252 DOI: 10.2174/1570159x17666181227165722] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 23.0] [Reference Citation Analysis]
87 Carneiro L, Leloup C. Mens Sana in Corpore Sano: Does the Glycemic Index Have a Role to Play? Nutrients 2020;12:E2989. [PMID: 33003562 DOI: 10.3390/nu12102989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Shen Z, Liao X, Shao Z, Feng M, Yuan J, Wang S, Gan S, Ha Y, He Z, Jie W. Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability. BMC Cancer 2019;19:262. [PMID: 30902084 DOI: 10.1186/s12885-019-5482-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
89 Maslyonkina KS, Konyukova AK, Alexeeva DY, Sinelnikov MY, Mikhaleva LM. Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression. Cancer Med 2021. [PMID: 34870375 DOI: 10.1002/cam4.4447] [Reference Citation Analysis]
90 Pasculli B, Barbano R, Parrella P. Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Semin Cancer Biol 2018;51:22-35. [PMID: 29339244 DOI: 10.1016/j.semcancer.2018.01.007] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 14.8] [Reference Citation Analysis]
91 Garmpis N, Damaskos C, Garmpi A, Georgakopoulou VE, Sarantis P, Antoniou EA, Karamouzis MV, Nonni A, Schizas D, Diamantis E, Koustas E, Farmaki P, Syllaios A, Patsouras A, Kontzoglou K, Trakas N, Dimitroulis D. Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities. J Pers Med 2021;11:223. [PMID: 33809844 DOI: 10.3390/jpm11030223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 Ghayad SE, Rammal G, Sarkis O, Basma H, Ghamloush F, Fahs A, Karam M, Harajli M, Rabeh W, Mouawad JE, Zalzali H, Saab R. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma. Cancer Biol Ther 2019;20:272-83. [PMID: 30307360 DOI: 10.1080/15384047.2018.1529093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
93 Li L, Liu W, Wang H, Yang Q, Zhang L, Jin F, Jin Y. Mutual inhibition between HDAC9 and miR-17 regulates osteogenesis of human periodontal ligament stem cells in inflammatory conditions. Cell Death Dis 2018;9:480. [PMID: 29691366 DOI: 10.1038/s41419-018-0480-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
94 Li J, Chen C, Yao M, Sun L, Gao H, Chigan J, Yang K. Hydroxamic acid with benzenesulfonamide: An effective scaffold for the development of broad-spectrum metallo-β-lactamase inhibitors. Bioorganic Chemistry 2020;105:104436. [DOI: 10.1016/j.bioorg.2020.104436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Wawruszak A, Kalafut J, Okon E, Czapinski J, Halasa M, Przybyszewska A, Miziak P, Okla K, Rivero-Muller A, Stepulak A. Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells. Cancers (Basel) 2019;11:E148. [PMID: 30691229 DOI: 10.3390/cancers11020148] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
96 Farooqi AA, Naqvi SK, Perk AA, Yanar O, Tabassum S, Ahmad MS, Mansoor Q, Ashry MS, Ismail M, Naoum GE, Arafat WO. Natural Agents-Mediated Targeting of Histone Deacetylases. Arch Immunol Ther Exp (Warsz) 2018;66:31-44. [PMID: 28852775 DOI: 10.1007/s00005-017-0488-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
97 Dimitrakopoulos FI, Kottorou A, Tzezou A. Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer. Cancer Lett 2021;517:55-65. [PMID: 34077785 DOI: 10.1016/j.canlet.2021.05.030] [Reference Citation Analysis]
98 Fiedor E, Zajda K, Gregoraszczuk EL. Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer. Cancer Genomics Proteomics 2018;15:329-36. [PMID: 29976638 DOI: 10.21873/cgp.20091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
99 Simeone TA, Simeone KA, Rho JM. Ketone Bodies as Anti-Seizure Agents. Neurochem Res 2017;42:2011-8. [PMID: 28397070 DOI: 10.1007/s11064-017-2253-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]